Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

Breyanzi (lisocabtagene maraleucel) is a type of treatment called a chimeric antigen receptor T-cell therapy (CAR T-cell) that uses your body's own immune system to treat your cancer. Breyanzi was ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

Bristol Myers Squibb (BMS) received U.S. Food and Drug Administration (FDA) approval for label updates for its CAR T cell ...

Breyanzi and its Previous Approvals. Breyanzi is a CD19-directed CAR T cell therapy that includes a 4-1BB costimulatory domain, which helps enhance the expansion and persistence of the CAR T cells in ...

“Breyanzi has opened the possibility of a complete and lasting response for the most threatened population of LBCL – those patients whose lymphoma doesn’t go away completely after first-line ...